Abstract 3869
Background
Children and adolescents with cancer are at risk of experiencing distress in relation to their cancer diagnosis, treatment and treatment-related procedures. Complementary therapies such as reflexology may be used to help alleviate distressing symptoms; however, there is a dearth of research regarding the experience of reflexology from the perspective of children/adolescents with cancer and/or the parents/guardians of those who have received these treatments. Objective: To ascertain the perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage.
Methods
Children and adolescents aged between 7 and 18 years attending a national children’s hospital for cancer treatment were invited to participate in a randomised controlled trial using a Mixed Between Group Repeated Measures design following receipt of ethical approval from the hospital’s Research Ethics Committee. In total, 75 children/adolescents either consented or assented to take part in the study. Of these, 39 were randomized to the intervention group (reflexology) and 36 to the control group (non-specific foot massage). Semi-structured interviews were undertaken with parents/guardians using an interview guide. Interviews were analysed using Braun and Clarke’s (2006) thematic analysis.
Results
The overarching theme which emerged across the interviews was participants’ perceptions of the foot treatments in general as a means of supporting the child during treatment for cancer. This central theme is discussed under a number of subthemes, namely psychological wellbeing, perceived physiological impact, time and space, a safe relationship and service development.
Conclusions
The parents/guardians views regarding the foot treatments in general were consistently positive. The implications of the study findings and the future delivery of the complementary therapy service will be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UCD.
Funding
Childhood Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract